BCL2 Suppresses PARP1 Function and Nonapoptotic Cell Death
Chaitali Dutta(Harvard University), David M. Weinstock(Broad Institute), Anthony Letai(Dana-Farber Cancer Institute), Tovah A. Day(Boston University), Naveen Kommajosyula(Harvard University), Geoffrey I. Shapiro(Brigham and Women's Hospital), Nadja Kopp(Dana-Farber Cancer Institute), Hua Fung(Dana-Farber Cancer Institute), Jeremy Ryan(Dana-Farber Cancer Institute), Liat Bird(Harvard University), Matthew S. Davids(Dana-Farber Cancer Institute), Diederik van Bodegom(Harvard University), Akinori Yoda(Kyoto University), Oliver Weigert(German Cancer Research Center), Jennifer R. Brown(Dana-Farber Cancer Institute)
Cited by 54
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k